Top Medical News
Abatacept may mitigate rheumatoid arthritis development in at-risk individuals
Jairia Dela Cruz, 23 Feb 2024
The use of abatacept in adults at high risk of rheumatoid arthritis helps protect against disease onset, as shown in the phase IIB APIPPRA study.
Serious infections prevalent in RTX-treated patients with SLE
13 Feb 2024
A recent study has reported the prevalence of serious infection (SI) among patients with systemic lupus erythematosus (SLE) following treatment with rituximab (RTX).
Is BASDAI a responsive instrument in PsA?
13 Feb 2024
Use of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) as an instrument in psoriatic arthritis (PsA) demonstrates “reasonable” responsiveness but falls short of distinguishing peripheral PsA from axial (ax)PsA, according to a recent study.
Hydroxychloroquine does little to prevent pre-eclampsia in pregnant women with lupus
05 Feb 2024
The use of hydroxychloroquine during pregnancy does not appear to reduce the risk of pre-eclampsia among women with systemic lupus erythematosus, as shown in a study.
Rituximab resolves complications in anti-MDA5–positive JDM
17 Jan 2024
Treatment with rituximab (RTX) in children with juvenile dermatomyositis (JDM) and antibodies to antimelanoma differentiation-associated gene 5 (anti-MDA5) results in clinical improvements in interstitial lung disease (ILD) as well as in cutaneous manifestation and musculoskeletal disease activity, according to a study.
Intensive diet for patients with obesity, gout helps with weight loss but not symptom reduction
14 Jan 2024
For patients with gout and obesity, an intensive dietary intervention leads to reductions in body weight, but the weight loss does not necessarily translate to improvements in serum urate, fatigue, and pain, according to a study.
Long-term supervised exercise works better than usual care in RA
10 Jan 2024
For people with rheumatoid arthritis (RA) and severe functional limitations, undergoing supervised exercise therapy for more than 52 weeks results in better outcomes compared with usual care, as reported in a study.
Special Reports
AZD7442 (tixagevimab–cilgavimab) prevents COVID-19 in high-risk populations
Dr. Leong Hoe Nam, Dr. Behram Ali Khan, Dr. See Hui Ti, Dr. Yoon Kam Hon, 12 Oct 2022

Though most COVID-19 safe management measures have been lifted in Singapore, the pandemic continues to adversely impact the lives of immunocompromised patients at high risk of severe infection. 

“It has been an absolute misery for these patients and their families,” said Dr Leong Hoe Nam, Infectious Disease Specialist at Mount Elizabeth Novena Hospital, Singapore. “The virus is an unseen enemy that may strike unexpectedly. The strike may kill, or if not, maim the individual. Patients isolate themselves for fear of getting infected while their family members fear bringing the illness back home.” 

Immunocompromised patients are those with suppressed immunity resulting from health conditions, including solid organ and haematological cancers, end-stage kidney and liver disease, organ or bone marrow transplants, and immune-mediated inflammatory diseases such as rheumatoid arthritis, or those on active treatment with immunosuppressive medications. [Expert Rev Vaccines 2022;1-17; BMJ 2021;374:n2098]

Managing comorbidities in rheumatoid arthritis in the new decade
Prof. Peter Taylor, Prof. Christopher Edwards, Dr. Lian Tsui Yee, 03 Nov 2021
Nearly half of all rheumatoid arthritis (RA) patients suffer comorbidity, which has a negative impact on quality of life and mortality. At a recent scientific symposium, Professor Peter Taylor from the University of Oxford in Oxford, UK emphasized the importance of monitoring, preventing, and treating comorbidities in RA while Professor Christopher Edwards from the University Hospital Southampton in Southampton, UK focused on the impact of mental health in RA. The symposium was organized by Fresenius Kabi and held under the auspices of the Singapore Society of Rheumatology. Dr Lian Tsui Yee from Tan Tock Seng Hospital, Singapore chaired the event.
Conference Reports
Real-world data back CV safety of JAK inhibitors
Audrey Abella, 28 Jun 2023
Two real-world studies presented at EULAR 2023 reflected the cardiovascular (CV) safety of Janus kinase inhibitors (JAKi*) in patients with rheumatoid arthritis (RA).
Uricase-based combo therapy promising for refractory gout
Elvira Manzano, 28 Jun 2023
Half of gout patients receiving novel uricase analogue infusions, along with a proprietary rapamycin formulation, got their serum urate controlled in two phase III studies presented at EULAR 2023.
SGLT2 inhibitors score big, this time in gout
Elvira Manzano, 22 Jun 2023
Patients initiated on gliflozins or flozins – also called sodium-glucose co-transporter 2 (SGLT2) inhibitors – for type 2 diabetes (T2D) who were previously on metformin had reductions in the incidents of gout of up to 60 percent compared with other second-line agents in a recent study.
Novel drug STRIDES in the right direction for knee OA
Audrey Abella, 21 Jun 2023
In the phase III STRIDES X-Ray Extension study, additional doses of the investigational CLK/DYRK inhibitor lorecivivint delivered favourable outcomes for individuals with advanced knee osteoarthritis (OA).
Dazodalibep reduces Sjögren’s syndrome-related symptoms
Elaine Soliven, 21 Jun 2023
Treatment with dazodalibep, a novel nonantibody fusion protein that acts as an antagonist of CD40 ligand, significantly reduced symptom burden in adults with Sjögren’s syndrome, according to the ALISS trial presented at EULAR 2023.
Romosozumab one-ups denosumab in boosting bone mineral density for chronic steroid users
Jairia Dela Cruz, 20 Jun 2023
In the treatment of chronic glucocorticoid users with high fracture risk, romosozumab yields higher gains in spine bone mineral density (BMD) compared with denosumab, as shown in a pilot trial presented at EULAR 2023.
Artificial intelligence, if used correctly can empower the world of medicine.
Stephen Padilla, 20 Jun 2023
It is now possible to predict rheumatoid arthritis (RA), thanks to interpretations of magnetic resonance imaging (MRI) scans made by an artificial intelligence (AI) model.